GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
18 avr. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
16 mars 2023 08h45 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new...
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
30 janv. 2023 08h30 HE
|
GeneDx Holdings Corp.
Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype...
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
09 janv. 2023 08h30 HE
|
GeneDx Holdings Corp.
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company’s common stock will trade on the Nasdaq under...
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
05 déc. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings...
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
31 oct. 2022 09h00 HE
|
Sema4
STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome...
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
26 oct. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing...
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
13 oct. 2022 08h00 HE
|
Sema4
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child...
Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Test Menu
04 déc. 2012 08h36 HE
|
Invivoscribe
SAN DIEGO, CA--(Marketwire - Dec 4, 2012) - Invivoscribe Technologies, Inc., a privately-held life science company based in San Diego, California, announces the launch of Genection, Inc.
...